Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > 2020 Exciting Year
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(227)
•••
Comment by DavidKingCanadaon Feb 04, 2022 11:41am
223 Views
Post# 34397831

RE:2020 Exciting Year

RE:2020 Exciting Year

bball67 wrote: I agree 100% that the first half of 2020 will begin a run that will make investors very happy. I invested in Promis 3 years ago in a private placement. I continued to buy over the past three years and now own 615k shares. I have had a lot of time to say no but the news and presentations presented a compelling case. I have spoken to a knowledgeable person familiar with the company in the last three months. They assured me that my evaluation and conclusions were spot on. I am a former SVP and CFO of start up retailer that grew from 11 stores to 1200 in my 18 years and obtained a market cap of $3+ billion. I know wall street very well and managed 20 analysts. Promis has an incredibly strong board-that doesnt happen by accident. They want to be associated with a blockbuster treatment. Do not listen to the drivel about dilution. Pay no attention to the "shorts" who market doubt and fear. From time to time companies become misunderstood and their stock price does not reflect it's true potential. It can go on for quite awhile. I believe that is what is happenning with Promis. The stock price is not going down from here. Do not sell is my advice.

 

Mr. Millionaire Bball

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities